---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-23-000088"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T15:02:10.483128+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "low"
source: SEC EDGAR
---

# Tarsus announces positive topline Phase 2a results for TP-03 in MGD with Demodex mites

## Summary
- Ersa trial evaluated TP-03 (lotilaner ophthalmic solution, 0.25%) BID or TID for 12 weeks.
- Trial enrolled Meibomian Gland Disease patients with Demodex mites.
- Company states positive topline results; detailed data presented in corporate deck.
- No specific efficacy or safety numbers disclosed in the 8-K filing.

## SEC filing metadata
- accession: 0001819790-23-000088
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979023000088/0001819790-23-000088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979023000088/tars-20231211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-23-000088
- JSON: https://secwatch.observer/filing/0001819790-23-000088.json
- Plain text: https://secwatch.observer/filing/0001819790-23-000088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.